5 recruiting, 4 completed, 1 not yet recruiting, 1 terminated. 3 Phase 3, 2 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Microscopic Polyangiitis (MPA): new trials by email Literature Review of Microscopic Polyangiitis (MPA) trials Research Report on Microscopic Polyangiitis (MPA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis. Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA) | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2026-02-01 | 2026-03-05 |
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| Ocular Manifestations of Granulomatosis With Polyangiitis. Optical coherence tomography angiography - GPA, Vasculitis | Recruiting | Military Institute od Medicine National Research Institute | 70 | 2024-03-01 | 2026-06-24 | |
| Special Drug Use-results Survey for Long-term Use（Avacopan） Avacopan - Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA) | Recruiting | Kissei Pharmaceutical Co., Ltd. | 250 | 2022-07-29 | 2025-01-17 | |
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Rituximab, placebo - Microscopic Polyangiitis (MPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 8 | 2020-10-24 | 2026-05-06 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA IFX-1 low dose, IFX-1 high dose, Placebo - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Terminated | InflaRx GmbH | 20 | 2018-10-15 | 2022-05-26 |
| Clinical Transcriptomics in Systemic Vasculitis (CUTIS) Cryoglobulinemic Vasculitis (CV), Drug-induced Vasculitis | Recruiting | Peter Merkel | 50 | 2017-01-01 | 2026-01-22 | |
| Vasculitis Pregnancy Registry Online questionnaires - Vasculitis, Behcet's Disease | Recruiting | University of Pennsylvania | 100 | 2015-11-01 | 2026-01-23 | |
| The ANCA Vasculitis Questionnaire (AAV-PRO©) Online questionnaire - Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss) (EGPA), Churg-Strauss Syndrome (CSS) | Completed | University of Pennsylvania | 280 | 2015-07-01 | 2017-05-04 | |
| Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose] - Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | Phase 3 | Completed | University of Pennsylvania | 704 | 2010-05-01 | 2020-05-26 |
Microscopic Polyangiitis (11) · Granulomatosis with Polyangiitis (9) · Vasculitis (6) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (5) · Churg-Strauss Syndrome (4) · Systemic Vasculitis (3) · Cryoglobulinemia, Familial Mixed (2) · IgA Vasculitis (2) · Polyarteritis Nodosa (2) · Behcet Syndrome (1) · Takayasu Arteritis (1) · Vasculitis, Central Nervous System (1)
Autoimmune Diseases (11) · Brain Diseases (11) · Cardiovascular Diseases (11) · Central Nervous System Diseases (11) · Cerebral Small Vessel Diseases (11) · Cerebrovascular Disorders (11) · Immune System Diseases (11) · Nervous System Diseases (11) · Skin Diseases (11) · Skin Diseases, Vascular (11) · Skin and Connective Tissue Diseases (11) · Vascular Diseases (11) · Lung Diseases (9) · Lung Diseases, Interstitial (9) · Respiratory Tract Diseases (9)
Rituximab (3) · Glucocorticoids (2) · Prednisone (2) · vilobelimab (2) · Cyclophosphamide (1) · Plasma Exchange (1) · Standard of Care (1) · avacopan (1)
University of Pennsylvania (3) · Assistance Publique - Hôpitaux de Paris (2) · InflaRx GmbH (2) · Kissei Pharmaceutical Co., Ltd. (1) · Military Institute od Medicine National Research Institute (1) · Ottawa Hospital Research Institute (1) · Peter Merkel (1)
United States (5) · Canada (4) · France (4) · Belgium (2) · Czechia (2) · Italy (2) · Japan (2) · Sweden (2) · United Kingdom (2) · Australia (1) · Denmark (1) · Germany (1) · Greece (1) · Mexico (1) · Netherlands (1)
Peter A Merkel, MD, MPH (2) · Peter A. Merkel, MD, MPH (2) · Anja Pfaff, PhD (1) · David Jayne, MD (1) · David Massicotte-Azarniouch, MD, MSc (1) · Joanna Robson, MD (1) · Korinna Pilz, MD, MS (1) · Luc Mouthon, MD PhD (1) · Megan Clowse, MD, MPH (1) · Michael Walsh, MD (1) · Peter Grayson, MD, MSc (1) · Peter Merkel, MD, MPH (1) · Robert Micheletti, MD (1)
PMID 32053298, PMID 33164993, PMID 36155131, PMID 38346237, PMID 38825350, PMID 38825354
2009 (1), 2018 (1), 2025 (1), U54AR057319 (1)